Cetera Investment Advisers
LTRN icon

Cetera Investment Advisers’s Lantern Pharma LTRN Stock Holding History

Cetera Investment Advisers’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.8K Hold
12,228
– – ﹤0.01% 4673
2025
Q4 		$37.1K Buy
+12,228
New +$45.5K ﹤0.01% 4540

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cetera Investment Advisers's LTRN Position: Q1 2026 in Review

Cetera Investment Advisers held its Lantern Pharma (LTRN) position steady in Q1 2026 at 12,228 shares worth $16.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4673.

Cetera Investment Advisers first reported a position in LTRN in Q4 2025 and has held it in 2 quarters since. The position peaked at $37.1K in Q4 2025. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • Cetera Investment Advisers held 12,228 shares of Lantern Pharma worth $16.8K as of Q1 2026.
  • Cetera Investment Advisers left its Lantern Pharma share count unchanged in Q1 2026.
  • Lantern Pharma made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #4673 holding.
  • Cetera Investment Advisers first reported a position in Lantern Pharma in Q4 2025 and has held it in 2 quarters since.
  • Cetera Investment Advisers's Lantern Pharma position peaked at $37.1K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.